Activity was measured by its action upon a pseudo substrate, citraconate
Full-length EPO, while potently tissue-protective, carries serious cardiovascular risks when used outside erythropoietic contexts due to increased haematocrit, thrombosis risk, and hypertension
The FAK-paxillin pathway activation enhances cell migration to injury sites
Symptoms include difficulty breathing, facial or throat swelling, rapid heartbeat, hives, and a sudden drop in blood pressure
Some people may experience mild digestive upset when they first start a supplement, but this often resolves quickly
Sikirics first published findings appeared in the Journal of Physiology, Paris in 1993